Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. ("Shangyao Zhongxi"), recently received the Drug Registration Certificate (Certificate No.: 2025S03257) issued by the National Medical Products Administration (NMPA) for Tofacitinib Citrate Sustained-Release Tablets, approving its production.

The medication is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Originally developed by Pfizer, it was first launched in the U.S. in 2016. In January 2024, Shangyao Zhongxi submitted a registration application for the drug to the NMPA, which was subsequently accepted.

As of the announcement date, the company has invested approximately RMB 19.42 million in R&D for this product.